Swiss Hepatitis Symposium
SAMMSU is a co-organizer of the Swiss Hepatitis Symposium 2024 on Surveillance & Response and will present the SAMMSU cohort as an important monitoring tool. Have you missed the symposium? Presentations are now available.
Call for project proposals
Are you involved in research in the field of addiction medicine? Do you have a research question that SAMMSU data could answer? We are happy to receive your project proposal. Please find the form for project proposals below. Fill it in and send it to [email protected].
| SAMMSU Project Proposal |
Posters 2014 - 2024
Bregenzer et al. 2024: Description of opioid agonist therapy in the Swiss Association for the Medical Management in Substance Users (SAMMSU) cohort: Poster at the INHSU Conference in Athens, October 2024.
| Bregenzer et al. inhsu2024_oat.pdf |
Bregenzer et al. 2024: HCV late presentation (severe fibrosis/cirrhosis at first HCV therapy or first HCV diagnosis) in the Swiss Association for the Medical Management in Substance Users (SAMMSU) cohort since 2017: Poster at the INHSU Conference in Athens, October 2024.
| Bregenzer et al. inhsu2024_late_presenters.pdf |
Bregenzer et al. 2024: HIV and HCV cascade, RNA prevalence and new diagnoses in opioid agonist therapy (OAT) patients
from the SAMMSU-cohort, Switzerland: Poster at the International AIDS conference in Munich, 2024.
from the SAMMSU-cohort, Switzerland: Poster at the International AIDS conference in Munich, 2024.
| Bregenzer et al. 2024_HIV_HCV.pdf |
Bregenzer et al. 2023: Current prevalence of and risk factors for liver cirrhosis in opioid agonist therapy patients of the SAMMSU cohort after 5 years of unrestricted DAA access, Poster at the INHSU Conference, Geneva, 2023.
| bregenzer_et_al_inhsu2023_liver_cirrhosis.pdf |
Bregenzer et al. 2023: Occurrence and outcome of hepatitis C reinfections in opioid agonist therapy patients of the SAMMSU cohort, Poster at the INHSU Conference, Geneva, 2023.
| bregenzer_et_al_inhsu2023_reinfections.pdf |
Moriggia et al. 2022: Late presentation of chronic hepatitis C in a Swiss cohort of people in opioid agonist therapy.
| Moriggia A. et al. 2022.pdf |
Castro et al. 2022: Mental disorders and hepatitis C prevalence in people in opioid agonist therapy followed at the SAMMSU cohort, Switzerland.
| Castro E. et al. INHSU 2022.pdf |
Bregenzer et al. 2019: The HIV and HCV cascade in Swiss opioid agonist treatment (OAT) patients the SAMMSU cohort.
| Bregenzer et al. EACS 2019.pdf |
Bregenzer et al. 2018: Feasibility, outcome and uptake of IFN-based and IFN-free DAA HCV-treatment in OST patients in Switzerland - The SAMMSU-Cohort.
| Bregenzer A. et al. INHSU 2018 |
Moriggia et al. 2017: Barriers to widespread hepatitis C treatment among people who inject drugs: data from the SAMMSU cohort.
| Moriggia A. et al. INHSU 2017 |
Moriggia et al. 2016: Prospective data on people who use drugs in Switzerland: the SAMMSU cohort.
| Moriggia A. et al. INHSU 2016 |
Castro et al.2015: Swiss data on hepatitis C treatment in people who use drugs: the SAMMSU cohort.
| Castro E. et al: Look back study INHSU 2015 |